• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

No increase in mortality with paclitaxel-coated devices among patients with femoropopliteal disease

byNeel MistryandTeddy Guo
December 13, 2023
in Cardiology, Chronic Disease, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. There was no significant increase in mortality between the paclitaxel-coated and control devices in both the intention-to-treat and as-treated analyses groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The safety of paclitaxel-coated devices for femoropopliteal disease has been well-studied; however, a 2018 meta-analysis raised concerns about increased mortality risk with paclitaxel. This meta-analysis aimed to provide updated insights on data from ten different trials comparing mortality rates between paclitaxel-coated and control (non-paclitaxel-coated) devices. The primary outcome was the effect of paclitaxel exposure on mortality, while key secondary outcomes were the impact of paclitaxel dose and baseline covariates. According to study results, there was no significant increase in mortality between the paclitaxel-coated and non-paclitaxel-coated devices. Although this study was well done, it was limited by variability in trial design and patient populations, affecting the validity of results.

Click to read the study in The Lancet

Relevant Reading: Mortality with Paclitaxel-Coated Devices in Peripheral Artery Disease

In-depth [meta-analysis]: Between 2005 and 2018, 10 trials were included comparing paclitaxel-coated versus control devices for femoropopliteal occlusive disease. Altogether, 2666 patients were included in the final analysis, with a median follow-up of 4.9 years. The primary outcome reported no significant increase in deaths associated with paclitaxel-coated devices (hazard ratio [HR] 1.14, 95% confidence interval [CI] 0.93-1.40). Similarly, the unadjusted HR for all-cause mortality comparing paclitaxel-coated and control-treated participants was 1.02 (95% CI 0.78-1.34), offering reassurance to patients, physicians, and regulators on their safety. Overall, findings from this study suggest that paclitaxel-coated devices do not pose an increased risk of mortality.

RELATED REPORTS

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: claudicationfemoropopliteal diseaseinterventional radiologypaclitaxelpaclitaxel-coated devicePeripheral Arterial Diseaseperipheral vascular diseasevascular surgery
Previous Post

COVID virologic rebound may occur in patients treated with nirmatrelvir-ritonavir

Next Post

A low-inflammatory diet is associated with a lower incidence of diabetes

RelatedReports

Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
Chronic Disease

Retifanlimab improves progression-free survival in advanced squamous cell anal carcinoma

July 24, 2025
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Chronic Disease

Relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer patients

July 23, 2025
Increased number of daily steps linked with decreased mortality in older women
Chronic Disease

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

May 29, 2025
#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer
StudyGraphics

#VisualAbstract: Perioperative Chemotherapy is Superior to Preoperative Chemoradiotherapy in Esophageal Cancer

February 7, 2025
Next Post

A low-inflammatory diet is associated with a lower incidence of diabetes

The 2 Minute Medicine Podcast Episode 15

The 2 Minute Medicine Podcast Episode 30

Few older adolescents meet recommended levels of physical activity

Wellness Check: Exercise

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Microneedling with tranexamic acid may improve outcomes for patients with melasma
  • Long term safety and efficacy of rabies monoclonal antibody in post-exposure prophylaxis
  • Tirzepatide leads to greater weight loss than semaglutide among adults with obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.